Zepbound KwikPen launches through LillyDirect at $299 a month for 2.5 mg

Eli Lilly said on Feb. 23, 2026, that the FDA approved a label expansion for Zepbound (tirzepatide) to include a four-dose KwikPen, a single device that holds a full month of the injectable weight-loss drug ^[1][2]. Patients who pay out of pocket through Lilly's direct-to-consumer platform, LillyDirect, can now get any of the drug's six doses in either the new multi-dose KwikPen or the existing single-dose vial for the same price, starting at $299 a month for the 2.5 mg starting dose ^[1][2].

The KwikPen will be available in all six approved Zepbound doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg ^[2]. Lilly already uses the same pen design to deliver its diabetes drug Mounjaro, and the device has been sold in other countries, including the United Kingdom, Australia, and Canada ^[1][2]. Lilly cited IQVIA prescription data in calling Zepbound the most prescribed weight-management medication in 2025 and said it has overtaken Novo Nordisk's Wegovy as the U.S. weight-loss market leader by prescriptions ^[1][2].

According to Lilly, more than 1 million patients used LillyDirect in 2025, and one out of every three new patients starting a branded weight-loss drug that year was prescribed a Zepbound self-pay vial ^[1]. Outside pricing research shows the LillyDirect self-pay program has tiered pricing for the vial option: $299 a month for the 2.5 mg starting dose, $399 for 5 mg, and $449 for 7.5 mg through 15 mg maintenance doses, as long as patients refill within 45 days ^[3]. That same source lists Zepbound's list price, before any discount, at $1,086 a month ^[3]. It is not stated in the sources whether the new KwikPen follows this same tiered structure above 2.5 mg or whether it holds at $299 across all doses.

The LillyDirect self-pay channel cannot be combined with commercial insurance, Medicare, or Medicaid ^[3]. Separately, a Medicare GLP-1 Bridge demonstration program is set to begin covering Zepbound for obesity at a $50 monthly copay starting July 1, 2026, running through the end of 2027, according to research compiled outside Lilly's announcement ^[3]. Medicare Part D already can cover Zepbound when prescribed for moderate-to-severe obstructive sleep apnea in adults with obesity ^[3].

Why it matters for patients

For patients who pay cash rather than use insurance, the new KwikPen gives a choice of device without changing the starting price: $299 a month for the 2.5 mg dose, matching what LillyDirect already charges for the single-dose vial ^[1][2]. A multi-dose pen means one device covers a full month, rather than four separate single-dose units, which may simplify handling and storage for some patients, though the sources do not detail differences in how the two devices are used.

The timing also matters because it comes as Zepbound's market position has shifted. Lilly says prescription data shows Zepbound passed Wegovy as the top-selling obesity drug in the U.S. in 2025 ^[1][2]. Patients comparing options may weigh this alongside head-to-head trial data Lilly cites from the SURMOUNT-5 study, an open-label 72-week trial in which people on Zepbound's highest tolerated dose lost an average of 20.2% of body weight (about 50 pounds), compared with 13.7% (about 33 pounds) for people on Wegovy's highest tolerated dose ^[1][2]. Lilly's own materials note this was a less rigorous, open-label design, meaning the findings are less certain than a blinded trial ^[1].

Pricing and insurance rules for GLP-1 drugs remain complicated and vary by coverage type, dose, and indication. The LillyDirect self-pay option cannot be combined with commercial insurance, Medicare, or Medicaid ^[3], so patients with those types of coverage would need to compare their formulary benefits, manufacturer savings cards, or emerging Medicare pathways against the LillyDirect cash price.

What happens next

The Medicare GLP-1 Bridge program is set to begin covering Zepbound for obesity, not just OSA, at a $50 monthly copay starting July 1, 2026, and continuing through Dec. 31, 2027, based on research compiled independently of Lilly's announcement ^[3]. It is not yet known from these sources whether that Medicare pathway will apply to the new KwikPen device specifically or how pricing for doses above 2.5 mg in the KwikPen format will be structured long term.